Overview

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Status:
Completed
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to severe pruritus.
Phase:
Phase 2
Details
Lead Sponsor:
Cara Therapeutics, Inc.